Ontology highlight
ABSTRACT: Background
We aim to evaluate the safety and efficacy of mistletoe extract (ME) use during the oncological perioperative period.Methods
Details registered a priori on PROSPERO (CRD42018086168).Results
Seven RCTs (comprising 663 participants in nine reports) and three nonrandomized studies were included. In five RCTs, ME was evaluated as adjunctive care and the control group had no additional intervention, whereas in two RCTs, ME was compared head-to-head against common cancer treatments (i.e., etoposide or bacillus Calmette-Guérin) with the intervention groups not receiving standard care. Meta-analyses found no evidence for a difference between ME and no added therapy for mortality and recurrence (RR, 95% CI: 1.00, 0.79-1.27; and 1.03, 0.79-1.33, respectively). Two
SUBMITTER: Cogo E
PROVIDER: S-EPMC10529072 | biostudies-literature | 2023 Sep
REPOSITORIES: biostudies-literature